IP Library Granted Patent US 10,981,970
Granted Patent B2
US 10,981,970 · App. 16/024,445 · Granted Apr 20, 2021

Chimeric antigen receptor (CAR) comprising a CD22-binding domain

Inventors: Martin Pulé (London, GB); Shaun Cordoba (London, GB); Shimobi Onuoha (London, GB); Simon Thomas (London, GB)
Assignee: AUTOLUS LIMITED
C07K14/70521A61K35/17A61K38/1774A61K39/0011A61K39/001113C07K14/7051C07K14/70535C07K16/2803C07K16/2863C07K16/3061C12N5/0636C12N5/0638A61K35/00A61K2039/505A61K2039/5158C07K2317/31C07K2317/622C07K2319/03C07K2319/74C12N2501/505C12N2501/599C12N2510/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,981,970
App. No.
16/024,445
Granted
Apr 20, 2021
Kind
B2
Abstract

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

Claims (53)

1. A chimeric antigen receptor (CAR) comprising a CD22-binding domain which comprises:

a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:

CDR1

(SEQ ID NO: 27)

NYWIN,

CDR2

(SEQ ID NO: 28)

NIYPSDSFTNYNQKFKD,

and

CDR3

(SEQ ID NO: 29)

DTQERSWYFDV;

and

b) a light chain variable region (VL) having CDRs with the following sequences:

CDR1

(SEQ ID NO: 30)

RSSQSLVHSNGNTYLH,

CDR2

(SEQ ID NO: 31)

KVSNRFS,

and

CDR3

(SEQ ID NO: 32)

SQSTHVPWT.

2. A CAR according to claim 1 , wherein the CD22 binding domain comprises a VH domain having the sequence shown as SEQ ID NO: 35 or SEQ ID NO: 36, or a VL domain having the sequence shown as SEQ ID NO: 37 or SEQ ID NO: 38.

3. A CAR according to claim 1 , wherein the CD22 binding domain comprises the sequence shown as SEQ ID NO: 33 or SEQ ID NO: 34.

4. A cell comprising a CAR according to claim 1 .

5. A nucleic acid sequence encoding a CAR according to claim 1 .

6. A vector which comprises a nucleic acid sequence according to claim 5 .

7. A method for making a cell comprising CAR comprising a CD22-binding domain which comprises:

a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:

CDR1

(SEQ ID NO: 27)

NYWIN,

CDR2

(SEQ ID NO: 28)

NIYPSDSFTNYNQKFKD,

CDR3

(SEQ ID NO: 29)

DTQERSWYFDV;

and

b) a light chain variable region (VL) having CDRs with the following sequences:

CDR1

(SEQ ID NO: 30)

RSSQSLVHSNGNTYLH,

CDR2

(SEQ ID NO: 31)

KVSNRFS,

CDR3

(SEQ ID NO: 32)

SQSTHVPWT,

wherein the method comprises the step of introducing into a cell a nucleic acid sequence encoding the CAR or a vector comprising a nucleic acid encoding the CAR.

8. A pharmaceutical composition comprising a plurality of cells according to claim 4 .

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 27, 2025
From: BXLS V - AUTOBAHN L.P.
To: AUTOLUS LIMITED
Reel/Frame 071229/0607 →
SECURITY INTEREST Recorded Dec 6, 2021
From: AUTOLUS LIMITED
To: BXLS V - AUTOBAHN L.P.
Reel/Frame 058322/0796 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2020
From: UCL BUSINESS LTD
To: AUTOLUS LIMITED
Reel/Frame 054546/0758 →
CHANGE OF NAME Recorded Oct 9, 2019
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 050677/0190 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2018
From: PULE, MARTIN; CORDOBA, SHAUN; ONUOHA, SHIMOBI; THOMAS, SIMON
To: UCL BUSINESS PLC; AUTOLUS LIMITED
Reel/Frame 047641/0980 →
Priority Claims (1)
GB 1423172 · Dec 24, 2014 · national
Continuity (3)
Continuation 15631948 · Jun 23, 2017
Continuation 15529690
Related Publication 20180371054A1 · Dec 27, 2018
Cited By (3)
US 12,269,888 US 12,398,194 US 12,692,313